

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
07190808 190	Creatine Kinase-MB (100 tests)	System-ID 07 7484 7
11447394 216	Calibrator f.a.s. CK-MB (3 x 1 mL)	System-ID 07 7996 2
11447378 122	Precinorm CK-MB (4 x 3 mL)	System-ID 07 9111 3
04358210 190	Precipath CK-MB (4 x 3 mL)	System-ID 07 6828 6
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	System-ID 07 7469 3
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	System-ID 07 7469 3
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	System-ID 07 7470 7
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	System-ID 07 7470 7
20756350 322	NaCl Diluent 9 % (6 x 22 mL)	System-ID 07 5635 0

English

System information

Test CKMB2, test ID 0-057

Intended use

In vitro test for the quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma on COBAS INTEGRA systems.

Summary

Creatine kinase (CK) appears as three isoenzymes which are dimers composed of two types of monomer subunits. The isoenzymes comprise all three combinations of monomers, M (for skeletal muscle derived) and B (for brain derived), as represented by the notations MM, MB, and BB.¹

Many organs contain CK, but the distribution of isoenzymes is different in each one. Skeletal muscle is very rich in the MM isoenzyme, while brain, stomach, intestine, bladder, and lung contain primarily the BB isoenzyme. The MB isoenzyme has been found in appreciable amounts (15 to 20 percent) only in myocardial tissue. Therefore, total serum CK activity is elevated in a number of diseases. This lack of specificity limits its diagnostic value. However, the striking difference in the CK isoenzyme patterns from different organs has made CK one of the most useful enzymes for diagnostic purposes in acute myocardial infarction. CK-MB appears in serum reflecting its unique presence in myocardial tissue. It is in supporting the diagnosis of suspected myocardial infarction that serial determinations of CK isoenzymes find their most frequent application in the clinical laboratory.^{1,2}

After immunoinhibition with antibodies to the CK-M subunit,³ the CK-B activity is determined with a standardized method for the determination of CK with activation by NAC as recommended by the German Society for Clinical Chemistry (DGKC)⁴ and the International Federation of Clinical Chemistry (IFCC)^{5,6} in 1977 and 2002 respectively. This assay meets the recommendations of the IFCC and DGKC, but was optimized for performance and stability.

Test principle

Immunological UV assay

- Sample and addition of R1 (buffer/enzymes/coenzyme)
 - Addition of R2 (buffer/substrate/antibody) and start of reaction.
- Human CK-MB is composed of two subunits, CK-M and CK-B which both have an active site. With the aid of specific antibodies to CK-M, the catalytic activity of CK-M subunits in the sample is inhibited to 99.6 % without affecting the CK-B subunits. The remaining CK-B activity, corresponding to half the CK-MB activity, is determined by the total CK method. As the CK-BB isoenzyme only rarely appears in serum and the catalytic activity of the CK-M and CK-B subunits hardly differ, the catalytic activity of the CK-MB isoenzyme can be calculated from the measured CK-B activity by multiplying the result by 2.

Reagents - working solutions

R1 Imidazole buffer: 123 mmol/L, pH 6.5 (37 °C); EDTA: 2.46 mmol/L; Mg²⁺: 12.3 mmol/L; ADP: 2.46 mmol/L; AMP: 6.14 mmol/L; diadenosine pentaphosphate: 19 µmol/L; NADP (yeast): 2.46 mmol/L; N-acetylcysteine: 24.6 mmol/L; HK (yeast): ≥ 36.7 µkat/L; G6P-DH (E. coli): ≥ 23.4 µkat/L; preservative; stabilizers; additives.

SR CAPSO* buffer: 20 mmol/L, pH 8.8 (37 °C); glucose: 120 mmol/L; EDTA: 2.46 mmol/L; creatine phosphate: 184 mmol/L; 4 monoclonal anti-CK-M antibodies (mouse), inhibiting capacity: > 99.6 % up to 66.8 µkat/L (4000 U/L) (37 °C) CK-M subunit; preservative; stabilizers; additive.

*CAPSO: 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid

R1 is in position B and SR is in position C.

Precautions and warnings

Pay attention to all precautions and warnings listed in Section 1 / Introduction of this Method Manual.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Danger

H360D May damage the unborn child.

Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling primarily follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Reagent handling

Ready for use

Storage and stability

Shelf life at 2-8 °C

On-board in use at 10-15 °C

See expiration date on **cobas c** pack label

8 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum: Nonhemolyzed serum is the specimen of choice and also recommended by IFCC.

Plasma: Li-heparin, K₂, K₃-EDTA plasma.

Li-heparin in the usual concentration does not interfere with the test, but IFCC warns against its use.⁵

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability in serum: ⁷	8 hours at 20-24 °C
	8 days at 2-8 °C
	4 weeks at -20 °C
Stability in heparin plasma: ⁷	8 hours at 20-24 °C
	5 days at 2-8 °C
	8 days at -20 °C
Stability in EDTA plasma: ⁸	2 days at 20-25 °C
	7 days at 4-8 °C
	1 year at -20 °C

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

NaCl Diluent 9 %, Cat. No. 20756350322, system-ID 07 5635 0 for automatic sample dilution. NaCl Diluent 9 % is placed in its predefined rack position and is stable for 4 weeks on-board COBAS INTEGRA 400 plus analyzers.

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Application for serum and plasma**COBAS INTEGRA 400 plus test definition**

Measuring mode	Absorbance
Abs. calculation mode	Kinetic
Reaction mode	R1-S-SR
Reaction direction	Increase
Wavelength A/B	340/552 nm
Calc. first/last	10/50-69
Unit	U/L

Pipetting parameters

		Diluent (H ₂ O)
R1	100 µL	-
Sample	5 µL	-
SR	20 µL	-
Total volume	125 µL	

Calibration

Calibrator	C.f.a.s. CK-MB
	Use deionized water as zero calibrator.
Calibration mode	Linear regression
Calibration replicate	Duplicate recommended
Calibration interval	Each lot and as required following quality control procedures

Traceability: This method has been standardized against the IFCC Method for Creatine Kinase⁶ with addition of antibodies.

Quality control

Reference range	Precinorm CK-MB or PreciControl ClinChem Multi 1
Pathological range	Precipath CK-MB or PreciControl ClinChem Multi 2
Control interval	24 hours recommended
Control sequence	User defined
Control after calibration	Recommended

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

COBAS INTEGRA analyzers automatically calculate the analyte activity of each sample. For more details, please refer to Data Analysis in the Online Help (COBAS INTEGRA 400 plus analyzer).

Conversion factor: U/L x 0.0167 = µkat/L

Limitations - interference

The total CK activity of the specimen should be determined prior to performing the CK-MB assay. The amount of anti-human CK-M subunit antibody in the CK-MB reagent is sufficient for the complete inhibition of up to 4000 U/L CK-M activity. If the total CK activity exceeds 4000 U/L, the specimen requires dilution because complete inhibition of the CK-M subunit is no longer assured. In patients with a disposition to macro-CK formation, implausibly high CK-MB values may be measured in relation to the total CK, since the macroforms mainly consist of CK-B subunits. As these patients have generally not suffered a myocardial infarction, additional diagnostic measures are necessary.⁹

Criterion: Recovery within ± 10 % of initial value at a creatine kinase-MB activity of ≥ 25 U/L (≥ 0.42 µkat/L).

Icterus:¹⁰ No significant interference up to an I index of 60 for conjugated and 20 for unconjugated bilirubin (approximate conjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL and approximate unconjugated bilirubin concentration: 342 µmol/L or 20 mg/dL).

Hemolysis:¹⁰ No significant interference up to an H index of 20 (approximate hemoglobin concentration: 12.4 µmol/L or 20 mg/dL).

Lipemia (Intralipid):¹⁰ No significant interference up to an L index of 500. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration. Choose diluted sample treatment for automatic rerun.

Adenylate kinase: Adenylate kinase (AK) may cause positive interference. Sources of AK in the blood are erythrocytes, muscle, and liver. In order to reduce AK interference to a minimum, AMP and Ap₅A are included in the reagent. The AMP/Ap₅A mixture causes 97 % inhibition of the AK from erythrocytes and muscle, and 95 % inhibition of the AK from liver.⁴ The slight residual AK activity does not influence the assay of total CK, but may affect the low CK-MB activities.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{11,12}

Exceptions: Cyanokit (hydroxocobalamin), Cefoxitin, Sulfasalazine and Sulfapyridine at therapeutic concentrations interfere with the test.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹³

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the CLEAN Method Sheet for further instructions and for the latest version of the Extra wash cycle list.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

3-2000 U/L (0.05-33.4 µkat/L)

Determine samples having higher activities via the rerun function. Dilution of samples via the rerun function is a 1:3 dilution. Results from samples diluted by the rerun function are automatically multiplied by a factor of 3.

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 3 U/L (0.05 µkat/L)

Limit of Detection = 3 U/L (0.05 µkat/L)

Limit of Quantitation = 5 U/L (0.08 µkat/L)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the limit of blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a precision of 20 % CV. It has been determined using low concentration creatine kinase-MB samples.

Expected values

Reference intervals strongly depend on the patient group regarded and the specific clinical situation.

For healthy people: Reference range (37 °C) according to Klein et al.¹⁴ and consensus values:¹⁵

< 25 U/L (< 0.418 µkat/L)

For myocardial infarction diagnosis using the combination CK and CK-MB (activity), and representing a CK consensus value based on long-term experience:^{15,16}

1. CK_{men} > 190 U/L (3.17 µkat/L)
CK_{women} > 167 U/L (2.79 µkat/L)
2. CK-MB > 24 U/L (0.40 µkat/L)
3. The CK-MB activity accounts for 6-25 % of the total CK activity.

When myocardial infarction is suspected the diagnostic strategy proposals in the consensus document of European and American cardiologists should in general be followed.¹⁷

If despite the suspicion of myocardial infarction the values found remain below the stated limits, a fresh infarction may be involved. In such cases the determinations should be repeated after 4 hours.

Maximum diagnostic efficiency of the CK-MB determination will be obtained when a sequential sampling protocol is used and consideration is given to the time pattern of activity over a 6 to 48 hour period. When only CK-MB

activity is used, the diagnostic efficiency will be lower and will vary with the sampling time.^{1,9}

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Repeatability and intermediate precision were determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained:

<i>Repeatability</i>	<i>Mean</i> U/L (µkat/L)	<i>SD</i> U/L (µkat/L)	<i>CV</i> %
Human serum 1	22.2 (0.37)	0.7 (0.01)	3.2
Human serum 2	31.6 (0.53)	0.5 (0.01)	1.7
Human serum 3	562 (9.39)	3.0 (0.05)	0.5
Human serum 4	1105 (18.5)	7.0 (0.12)	0.6
Human serum 5	1949 (32.6)	27 (0.45)	1.4
PCCC Multi 1*	44.5 (0.74)	0.6 (0.01)	1.3
PCCC Multi 2	106 (1.77)	0.8 (0.01)	0.7

<i>Intermediate precision</i>	<i>Mean</i> U/L (µkat/L)	<i>SD</i> U/L (µkat/L)	<i>CV</i> %
Human serum 1	22.2 (0.37)	0.8 (0.01)	3.8
Human serum 2	31.6 (0.53)	0.7 (0.01)	2.2
Human serum 3	562 (9.39)	5.0 (0.08)	0.9
Human serum 4	1085 (18.1)	9.8 (0.16)	0.9
Human serum 5	1949 (32.6)	34 (0.57)	1.7
PCCC Multi 1	43.5 (0.73)	0.8 (0.01)	1.8
PCCC Multi 2	104 (1.74)	1.6 (0.03)	1.5

*PCCC = PreciControl ClinChem

Method comparison

Creatine kinase-MB values for human serum and plasma samples obtained on a COBAS INTEGRA 400 plus analyzer (y) were compared with those using the corresponding reagent on a Roche/Hitachi MODULAR P analyzer (x).

Sample size (n) = 117

Passing/Bablok ¹⁸	Linear regression
$y = 1.016x + 3.75 \text{ U/L}$	$y = 1.011x + 4.26 \text{ U/L}$
$r = 0.897$	$r = 1.000$

The sample activities were between 5.0 and 1967 U/L (0.08 and 32.8 µkat/L).

References




- 1 Moss DW, Henderson AR, Kachmar JF. Enzymes. In: Tietz NW, ed. Fundamentals of Clinical Chemistry, 3rd ed. Philadelphia, PA: WB Saunders 1987;346-421.
- 2 Lott JA, Stang JM. Serum enzymes and isoenzymes in the diagnosis and differential diagnosis of myocardial ischemia and necrosis. Clin Chem 1980;26:1241-1250.
- 3 Würzburg U, Hennrich N, Lang H, et al. Determination of creatine kinase-MB in serum using inhibiting antibodies. Klin Wschr 1976;54(8):357-360.

- 4 Bergmeyer HU, Breuer H, Büttner H, et al. Empfehlungen der Deutschen Gesellschaft für Klinische Chemie. Standard-Methode zur Bestimmung der Aktivität der Creatin-Kinase. J Clin Chem Clin Biochem 1977;15:249-254.
- 5 Hørdler M, Elser RC, Gerhardt W, et al. IFCC methods for the measurement of catalytic concentration of enzymes. Provisional recommendation IFCC method for creatine kinase Appendix A. J Int Fed Clin Chem 1990;2:26-35.
- 6 Schumann G, Bonora R, Ceriotti F, et al. IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37 °C – Part 2. Reference Procedure for the Measurement of Catalytic Concentration of Creatine Kinase. Clin Chem Lab Med 2002;40(6):635-642.
- 7 Braun S, Rösenthaller F, Jarausch J, et al. Analyte Stability of CK-MB Activity and cTnT in ICU Patient Serum and Heparin Plasma. Poster presented at Medica 2004, Düsseldorf. (Roche Diagnostics GmbH No. 04587979990).
- 8 Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2. Jan. 2002.
- 9 Remaley AT, Wilding P. Macroenzymes: Biochemical Characterization, Clinical Significance, and Laboratory Detection. Clin Chem 1989;35:2261-2270.
- 10 Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- 11 Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- 12 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- 13 Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- 14 Klein G, Berger A, Bertholf R, et al. Abstract: Multicenter Evaluation of Liquid Reagents for CK, CK-MB and LDH with Determination of Reference Intervals on Hitachi Systems. Clin Chem 2001;47:Suppl. A30.
- 15 Thomas L, Müller M, Schumann G, et al. Consensus of DGKL and VDGH for interim reference intervals on enzymes in serum. J Lab Med 2005; 29(5):301-308.
- 16 Stein W. Strategie der klinischen-chemischen Diagnostik des frischen Myokardinfarktes. Med Welt 1985;36:572-577.
- 17 Myocardial Infarction Redefined - A Consensus Document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-1513.
- 18 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS C, PRECICONTROL, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

